![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KCNMB3 |
Gene summary for KCNMB3 |
![]() |
Gene information | Species | Human | Gene symbol | KCNMB3 | Gene ID | 27094 |
Gene name | potassium calcium-activated channel subfamily M regulatory beta subunit 3 | |
Gene Alias | BKBETA3 | |
Cytomap | 3q26.32 | |
Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q9NPA1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27094 | KCNMB3 | HCC1_Meng | Human | Liver | HCC | 1.63e-39 | 1.66e-01 | 0.0246 |
27094 | KCNMB3 | HCC2_Meng | Human | Liver | HCC | 6.21e-06 | 6.23e-02 | 0.0107 |
27094 | KCNMB3 | HCC1 | Human | Liver | HCC | 5.67e-13 | 3.11e+00 | 0.5336 |
27094 | KCNMB3 | HCC2 | Human | Liver | HCC | 2.53e-18 | 2.22e+00 | 0.5341 |
27094 | KCNMB3 | HCC5 | Human | Liver | HCC | 6.74e-06 | 1.81e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001003822 | Liver | HCC | response to metal ion | 208/7958 | 373/18723 | 1.35e-07 | 2.56e-06 | 208 |
GO:005159221 | Liver | HCC | response to calcium ion | 81/7958 | 149/18723 | 2.26e-03 | 1.13e-02 | 81 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KCNMB3 | SNV | Missense_Mutation | rs572067352 | c.535N>A | p.Asp179Asn | p.D179N | Q9NPA1 | protein_coding | deleterious(0.03) | benign(0.289) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KCNMB3 | SNV | Missense_Mutation | novel | c.607N>C | p.Lys203Gln | p.K203Q | Q9NPA1 | protein_coding | tolerated(0.22) | benign(0.153) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
KCNMB3 | SNV | Missense_Mutation | novel | c.407N>C | p.Gly136Ala | p.G136A | Q9NPA1 | protein_coding | deleterious(0.05) | benign(0.327) | TCGA-SL-A6JA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KCNMB3 | SNV | Missense_Mutation | novel | c.352C>T | p.His118Tyr | p.H118Y | Q9NPA1 | protein_coding | tolerated(0.16) | benign(0.031) | TCGA-5C-A9VH-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
KCNMB3 | SNV | Missense_Mutation | c.59G>A | p.Gly20Glu | p.G20E | Q9NPA1 | protein_coding | deleterious(0.04) | probably_damaging(0.914) | TCGA-DD-A4NG-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
KCNMB3 | SNV | Missense_Mutation | c.5N>G | p.Asp2Gly | p.D2G | Q9NPA1 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-NI-A4U2-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
KCNMB3 | SNV | Missense_Mutation | novel | c.506N>T | p.Asn169Ile | p.N169I | Q9NPA1 | protein_coding | tolerated(0.14) | possibly_damaging(0.522) | TCGA-L9-A8F4-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCNMB3 | SNV | Missense_Mutation | novel | c.425A>C | p.His142Pro | p.H142P | Q9NPA1 | protein_coding | deleterious(0.01) | possibly_damaging(0.707) | TCGA-22-1016-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
KCNMB3 | SNV | Missense_Mutation | c.36T>G | p.His12Gln | p.H12Q | Q9NPA1 | protein_coding | deleterious_low_confidence(0.02) | benign(0.001) | TCGA-60-2710-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | pemetrexed | SD | |
KCNMB3 | SNV | Missense_Mutation | novel | c.265N>G | p.Gln89Glu | p.Q89E | Q9NPA1 | protein_coding | tolerated(0.38) | benign(0.096) | TCGA-94-7033-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |